

Amendments to the Specification:

At the paragraph beginning at page 34, line 19, please amend the paragraph as follows:

All current anti-CMV chemotherapies focus upon inhibition of viral DNA replication, although specific mechanisms vary slightly among different agents. Clinical strains have emerged which exhibit cross-resistance to multiple drugs. The effect of leflunomide product on activity of drug-resistant virus was evaluated as follows. CMV strain D16 was isolated from the same patient as strain P8. However, unlike P8, D16 exhibits multi-drug resistance. Plaque reduction assays performed in HFF cultures as described above (results shown in Figure 6 ~~Figure 8~~) revealed equivalent sensitivity of these two isolates to A771726 ($ID_{50} \sim 40-60 \mu M$). Thus leflunomide-mediated inhibition of viral activity occurs independent of resistance to current clinical chemotherapeutic agents.